Evofem Biosciences jumps as contraceptive Phexxi's sales surge

Evofem Biosciences

05/08/2022 11:56

** Shares in Evofem Biosciences  EVFM.O  jump 20% to $1.08
premarket
    ** Co reports 42% jump in sales of women's contraceptive
Phexxi to $6 million, affirms sales forecast for the product at
$30 mln to $35 mln  urn:newsml:reuters.com:*:nPn1DjrDsa
    ** Expects data from late-stage trial of Phexxi for
prevention of chlamydia and gonorrhea in October
    ** 4 of 5 brokerages rate the stock "buy" or higher, 1
"sell"; their median PT is $3.50 - Refinitiv data
    ** Up to Thursday's close, stock had fallen 84% YTD

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))